Cardlytics Inc (NASDAQ:CDLX) Major Shareholder Clifford Sosin Buys 9,490 Shares

Cardlytics Inc (NASDAQ:CDLX) major shareholder Clifford Sosin purchased 9,490 shares of the company’s stock in a transaction on Wednesday, October 16th. The shares were bought at an average cost of $37.95 per share, with a total value of $360,145.50. Major shareholders that own 10% or more of a company’s shares are required to disclose their transactions with the SEC.

Clifford Sosin also recently made the following trade(s):

  • On Monday, October 14th, Clifford Sosin purchased 68,252 shares of Cardlytics stock. The shares were bought at an average cost of $38.85 per share, with a total value of $2,651,590.20.
  • On Monday, October 7th, Clifford Sosin purchased 40,000 shares of Cardlytics stock. The shares were bought at an average cost of $35.38 per share, with a total value of $1,415,200.00.
  • On Wednesday, October 9th, Clifford Sosin purchased 73,578 shares of Cardlytics stock. The shares were bought at an average cost of $34.78 per share, with a total value of $2,559,042.84.

Shares of NASDAQ:CDLX opened at $37.08 on Wednesday. The company has a market cap of $870.19 million, a P/E ratio of -17.33 and a beta of 1.49. The company has a quick ratio of 2.01, a current ratio of 2.01 and a debt-to-equity ratio of 0.79. Cardlytics Inc has a 52 week low of $9.80 and a 52 week high of $39.83. The business has a fifty day simple moving average of $35.66 and a 200-day simple moving average of $27.38.

Cardlytics (NASDAQ:CDLX) last announced its quarterly earnings data on Thursday, August 8th. The company reported ($0.12) EPS for the quarter, beating the Zacks’ consensus estimate of ($0.35) by $0.23. The business had revenue of $48.73 million during the quarter, compared to the consensus estimate of $43.77 million. Cardlytics had a negative return on equity of 66.01% and a negative net margin of 19.60%. The business’s revenue for the quarter was up 37.0% on a year-over-year basis. During the same quarter in the previous year, the business earned ($0.21) earnings per share. Sell-side analysts expect that Cardlytics Inc will post -1.08 earnings per share for the current fiscal year.

Large investors have recently made changes to their positions in the company. Bank of Montreal Can grew its position in Cardlytics by 16,371.4% during the second quarter. Bank of Montreal Can now owns 1,153 shares of the company’s stock valued at $30,000 after acquiring an additional 1,146 shares during the period. Oppenheimer Asset Management Inc. purchased a new stake in Cardlytics during the second quarter valued at about $60,000. Rockefeller Capital Management L.P. purchased a new stake in Cardlytics during the second quarter valued at about $85,000. Acadian Asset Management LLC purchased a new stake in Cardlytics during the second quarter valued at about $161,000. Finally, Royal Bank of Canada grew its position in Cardlytics by 166.5% during the second quarter. Royal Bank of Canada now owns 10,643 shares of the company’s stock valued at $276,000 after acquiring an additional 6,649 shares during the period. 84.08% of the stock is owned by institutional investors and hedge funds.

Several research firms have weighed in on CDLX. JPMorgan Chase & Co. set a $43.00 price target on Cardlytics and gave the stock a “buy” rating in a research report on Friday, August 9th. ValuEngine downgraded Cardlytics from a “hold” rating to a “sell” rating in a research report on Wednesday, October 2nd. SunTrust Banks raised their price target on Cardlytics from $25.00 to $35.00 and gave the stock a “buy” rating in a research report on Friday, August 9th. William Blair began coverage on Cardlytics in a research report on Monday, July 1st. They set an “outperform” rating for the company. Finally, Bank of America reissued a “buy” rating and set a $32.00 price target (up previously from $22.00) on shares of Cardlytics in a research report on Wednesday, July 24th. One analyst has rated the stock with a sell rating, one has given a hold rating and seven have issued a buy rating to the company’s stock. Cardlytics has an average rating of “Buy” and a consensus target price of $34.71.

Cardlytics Company Profile

Cardlytics, Inc operates a purchase intelligence platform in the United States and the United Kingdom. It operates in two segments, Cardlytics Direct and Other Platform Solutions. The company's platform is the Cardlytics Direct solution, a proprietary native bank advertising channel that enables marketers to reach consumers through their trusted and frequently visited online and mobile banking channels.

Read More: FAANG Stocks

Insider Buying and Selling by Quarter for Cardlytics (NASDAQ:CDLX)

Receive News & Ratings for Cardlytics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cardlytics and related companies with MarketBeat.com's FREE daily email newsletter.